What are sodium benzoate and sodium phenylacetate?

What Are Sodium Benzoate and Sodium Phenylacetate?

Sodium benzoate and sodium phenylacetate are nitrogen-scavenging medications that provide alternative pathways for waste nitrogen excretion in patients with hyperammonemia, particularly those with urea cycle disorders. These agents work by conjugating with amino acids to form compounds that can be excreted in urine, bypassing the defective urea cycle 1, 2.

Mechanism of Action

These medications function as metabolically active compounds that serve as alternatives to urea for nitrogen disposal:

Sodium phenylacetate:

• Conjugates with glutamine in the liver and kidneys via acetylation to form phenylacetylglutamine
• Phenylacetylglutamine is excreted by the kidneys through glomerular filtration and tubular secretion
• Removes two moles of nitrogen per mole of phenylacetate (identical nitrogen content to urea) 2

Sodium benzoate:

• Conjugates with glycine (preceded by acylation) to form hippuric acid
• Hippuric acid is rapidly excreted by the kidneys via glomerular filtration and tubular secretion
• Removes one mole of nitrogen per mole of benzoate 2

The formation of hippurate from benzoate occurs more rapidly than phenylacetylglutamine formation from phenylacetate, and hippurate elimination is faster than phenylacetylglutamine elimination 2.

Clinical Indications

These agents are indicated for:

• Acute hyperammonemia in patients with urea cycle disorders (ornithine transcarbamylase deficiency, carbamoyl phosphate synthetase deficiency, argininosuccinate synthetase deficiency, argininosuccinate lyase deficiency, arginase deficiency, N-acetylglutamate synthetase deficiency) 1, 2
• Generally initiated when serum ammonia levels exceed 150 μmol/l (255 μg/dl) 1
• Can be administered more rapidly than kidney replacement therapy and in conjunction with dialysis 1

Dosing Guidelines

Per consensus guidelines 1:

For patients <20 kg body weight:

• 250 mg/kg of each agent (sodium benzoate AND sodium phenylacetate)
• Given over 90-120 minutes as bolus, then as maintenance over 24 hours

For patients >20 kg body weight:

• 5.5 g/m² of each agent
• Given over 90-120 minutes as bolus, then as maintenance over 24 hours

Critical safety consideration: Maximum dose of sodium benzoate is 12 g daily, as high-dose benzoate can be toxic and potentially lethal within 1 hour 1.

Pharmacokinetics

Both agents exhibit nonlinear kinetics 2:

• Phenylacetate: Detected in plasma at end of infusion (Tmax ~2 hours), with plasma levels higher and present longer than benzoate
• Benzoate: Concentrations decline rapidly (Tmax ~1.5 hours) and become undetectable at 14-26 hours following standard dosing
• Both agents are dialyzed along with other small molecules during kidney replacement therapy 1

Clinical Efficacy

A landmark 25-year study of 299 patients with 1,181 episodes of acute hyperammonemia demonstrated 3:

• Overall survival: 84% (250 of 299 patients)
• Episode survival: 96% (1,132 of 1,181 episodes)
• Patients >30 days of age had better survival than neonates (98% vs 73%, p<0.001)
• Even 81% of comatose patients survived
• Neonates with peak ammonia >1,000 μmol/l had poorest outcomes (38% survival)

Important Safety Considerations

Toxicity risks 2, 4:

• Overdosage can cause cardiorespiratory failure/arrest, obtundation, hyperventilation, severe metabolic acidosis with large anion gap, hypernatremia, hyperosmolarity, progressive encephalopathy, cardiovascular collapse, and death
• Ambiguous prescriptions and inadequate cross-checking have led to fatal overdoses
• In overdose, discontinue immediately and institute hemodialysis (preferred) or peritoneal dialysis

Therapeutic plasma concentrations 5:

• Upper therapeutic limit for benzoate: ~4.5 mM
• Upper therapeutic limit for phenylacetate: ~3.5 mM
• Transient toxicity (dizziness, nausea, vomiting) can occur at higher levels

Integration with Other Therapies

These nitrogen scavengers should be used as part of comprehensive management 1:

• Stop protein intake immediately
• Provide adequate calories (≥100 kcal/kg daily) via IV glucose (8-10 mg/kg/min) and lipids (0.5-3 g/kg daily)
• Add urea cycle intermediates (L-arginine or L-citrulline) based on specific enzyme deficiency
• Consider kidney replacement therapy if inadequate response after 2 hours or if ammonia levels are critically elevated
• Reintroduce protein within 48 hours once ammonia stabilizes to prevent catabolism

The evidence strongly supports that prompt recognition and treatment with sodium phenylacetate and sodium benzoate, combined with other supportive therapies, effectively lowers plasma ammonia levels and improves survival in the majority of patients with urea cycle disorders 3.